Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-unit cord blood transplantation for high-risk hematological malignancy
ACTRN12606000303549Phase 2Withdrawn
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgrastim in hematopoietic malignancies, sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Time to neutrophil and platelet engraftment. Planned start Sep 2006; status: withdrawn.
02
Drugs
filgrastim
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12606000303549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000303549.